Endo Brand of Naloxone Hydrochloride | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Endo Brand Of Naloxone Hydrochloride
US Exclusivities

PharmaCompass Sponsored Ads

Contact Supplier

Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

Contact Supplier

Naloxone Hydrochloride

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

xyz-pharma-m-2025-01-20

Contact Supplier

Endo Brand of Naloxone Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

28 API Suppliers, 13 USDMF, 12 CEP/COS, 1 JDMF, 2 EU WC, 3 KDMF, 18 NDC API, 18 Listed Suppliers, $ API Reference Price

28 API Suppliers
13 USDMF
12 CEP/COS
1 JDMF
2 EU WC
3 KDMF
18 NDC API
18 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

56 Drugs in Development

56 Drugs in Development

INTERMEDIATES

10 Intermediate Suppliers

10 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

312 FDF Dossiers, 161 FDA Orange Book, 83 Europe, 15 Canada, 14 Australia, 7 South Africa, 32 Listed Dossiers

312 FDF Dossiers
161 FDA Orange Book
83 Europe
15 Canada
14 Australia
7 South Africa
32 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM;BUCCAL - EQ 2.1MG BASE;EQ 0.3MG BASE, FILM;BUCCAL - EQ 4.2MG BASE;EQ 0.7MG BASE, FILM;BUCCAL - EQ 6.3MG BASE;EQ 1MG BASE, SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 0.4MG/0.4ML (0.4MG/0.4ML), TABLET;SUBLINGUAL - EQ 2MG BASE;EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;SUBLINGUAL - EQ 8MG BASE;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 2MG/0.4ML (2MG/0.4ML), FILM;BUCCAL, SUBLINGUAL - EQ 12MG BASE;EQ 3MG BASE, FILM;BUCCAL, SUBLINGUAL - EQ 2MG BASE;EQ 0.5MG BASE, FILM;BUCCAL, SUBLINGUAL - EQ 4MG BASE;EQ 1MG BASE, FILM;BUCCAL, SUBLINGUAL - EQ 8MG BASE;EQ 2MG BASE

FILM;BUCCAL - EQ 2.1MG BASE;EQ 0.3MG BASE
FILM;BUCCAL - EQ 4.2MG BASE;EQ 0.7MG BASE
FILM;BUCCAL - EQ 6.3MG BASE;EQ 1MG BASE
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 0.4MG/0.4ML (0.4MG/0.4ML)
TABLET;SUBLINGUAL - EQ 2MG BASE;EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;SUBLINGUAL - EQ 8MG BASE;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 2MG/0.4ML (2MG/0.4ML)
FILM;BUCCAL, SUBLINGUAL - EQ 12MG BASE;EQ 3MG BASE
FILM;BUCCAL, SUBLINGUAL - EQ 2MG BASE;EQ 0.5MG BASE
FILM;BUCCAL, SUBLINGUAL - EQ 4MG BASE;EQ 1MG BASE
FILM;BUCCAL, SUBLINGUAL - EQ 8MG BASE;EQ 2MG BASE

RELATED EXCIPIENT COMPANIES

1 Minakem, 4 Rochem International Inc, 17 SPI Pharma, 2 Seqens, 1 DKSH, 1 Pharm-RX Chemical, 7 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 8 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Pramukh Pharmachem, 1 ACG Worldwide, 10 Actylis, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 16 BASF, 1 Bioplus Life Sciences, 10 Corel Pharma Chem, 6 DFE Pharma, 2 Finar, 7 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 37 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 23 Roquette, 7 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

79 Fillers, Diluents & Binders, 45 Coating Systems & Additives, 31 Direct Compression, 25 Taste Masking, 23 Granulation, 23 Thickeners and Stabilizers, 23 Controlled & Modified Release, 19 Lubricants & Glidants, 19 Disintegrants & Superdisintegrants, 18 Chewable & Orodispersible Aids, 15 Co-Processed Excipients, 11 Parenteral, 8 Solubilizers, 8 Topical, 7 Film Formers & Plasticizers, 6 API Stability Enhancers, 5 Empty Capsules, 4 Emulsifying Agents, 4 Vegetarian Capsules, 3 Rheology Modifiers, 2 Coloring Agents, 1 Surfactant & Foaming Agents

79 Fillers, Diluents & Binders
45 Coating Systems & Additives
31 Direct Compression
25 Taste Masking
23 Granulation
23 Thickeners and Stabilizers
23 Controlled & Modified Release
19 Lubricants & Glidants
19 Disintegrants & Superdisintegrants
18 Chewable & Orodispersible Aids
15 Co-Processed Excipients
11 Parenteral
8 Solubilizers
8 Topical
7 Film Formers & Plasticizers
6 API Stability Enhancers
5 Empty Capsules
4 Emulsifying Agents
4 Vegetarian Capsules
3 Rheology Modifiers
2 Coloring Agents
1 Surfactant & Foaming Agents

DIGITAL CONTENT

238 NEWS #PharmaBuzz

238 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 76 Finished Drug Prices

2 US Medicaid Prescriptions
76 Finished Drug Prices

MARKET PLACE

18 APIs, 10 FDF Dossiers

18 APIs
10 FDF Dossiers

PATENTS & EXCLUSIVITIES

184 US Patents, 3 US Exclusivities

184 US Patents
3 US Exclusivities

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 5 Others

3 EDQM
1 USP
5 Others

$ API Ref.Price (USD/KG) : 10,350 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

3 All

01 1AMPHASTAR PHARMS INC

02 1HIKMA

03 1SUMMIT BIOSCI

filter Product Reset all filters

3 All

01 3NALOXONE HYDROCHLORIDE

filter Exclusivity Expiration Date Reset all filters

3 All

01 12024-04-29

02 12026-03-07

03 12027-04-19

filter Exclusivity Code Reset all filters

3 All

01 3NP

Veranova Naloxone hydrochloride

Product Main Page

SUMMIT BIOSCI

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

NALOXONE HYDROCHLORIDE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NP

Exclusivity Expiration Date

2027-04-19

Application Number

215487

Product Number

1

Exclusivity Details

01

SUMMIT BIOSCI

NALOXONE HYDROCHLORIDE

RNA Therapeutics

Not Confirmed

SUMMIT BIOSCI

U.S.A

RNA Therapeutics

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

NALOXONE HYDROCHLORIDE

Exclusivity Code : NP

Exclusivity Expiration Date : 2027-04-19

Application Number : 215487

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

HIKMA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

NALOXONE HYDROCHLORIDE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NP

Exclusivity Expiration Date

2024-04-29

Application Number

212045

Product Number

1

Exclusivity Details

02

HIKMA

NALOXONE HYDROCHLORIDE

RNA Therapeutics

Not Confirmed

HIKMA

United Kingdom

RNA Therapeutics

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

NALOXONE HYDROCHLORIDE

Exclusivity Code : NP

Exclusivity Expiration Date : 2024-04-29

Application Number : 212045

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

AMPHASTAR PHARMS INC

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

NALOXONE HYDROCHLORIDE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NP

Exclusivity Expiration Date

2026-03-07

Application Number

208969

Product Number

1

Exclusivity Details

03

AMPHASTAR PHARMS INC

NALOXONE HYDROCHLORIDE

RNA Therapeutics

Not Confirmed

AMPHASTAR PHARMS INC

U.S.A

RNA Therapeutics

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

NALOXONE HYDROCHLORIDE

Exclusivity Code : NP

Exclusivity Expiration Date : 2026-03-07

Application Number : 208969

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?